Healthcare

The Capitol Health merger is the through-line of Integral's recent story. Bringing the two imaging networks together has roughly reset the scale of theBusiness— reflected in a trailing revenue base that has jumped well over 50 per cent year on year as the combined …

Trajan has assembled, through acquisitions and organic development, a portfolio spanning analytical consumables, devices and instruments used across laboratories in fields such as chromatography, sample preparation and biosciences. Its operations reach across Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, …

4DMedical's recent history is one of accumulating regulatory and commercial groundwork in its priority markets. Around late 2025 and early 2026 the company secured US Food and Drug Administration 510(k) clearance for its CT:VQ product — which it describes as a first-and-only CT-based ventilation-perfusion …

On 13 July 2026 Orthocell reported record quarterly revenue of $3.8 million for the June quarter, a 20 per cent lift on the March quarter and about 36 per cent higher than the prior corresponding period, capping what the company described as a record …

Shares are up more than 100 per cent over the past year on the back of the ISLA-101 dengue data, and the company continues to signal progress toward next-stage trials and strategic discussions.

Ceretas debuted on the ASX under the ticker CTS, raising approximately A$8 million at 25 cents per share through the issue of 32 million shares, for an impliedMarket Capitalisationof around A$18 million at the offer price.

The recent narrative has been dominated by half-year FY26 numbers and US commercialisation progress. Cyclopharm's core product, Technegas, is a technetium-based aerosol used in ventilation lung scans. After years of regulatory effort, US approval opened a large addressable market, and the currentInvestmentdebate is entirely …